Trajan accelerating adoption and growth of microsampling technologies
6 December 2019 Melbourne, Victoria, Australia Trajan Scientific and Medical (Trajan) announce the appointment of two new roles in their expanding Microsampling business to support global adoption of the portfolio. Led by Dr Anne Collins, the Microsampling business…
Trailblazing entrepreneurs on track to commercial success and healthcare impact
6 December 2019 Last night, the very best of our nation’s innovation ecosystem helped promising entrepreneurs strike out towards commercial success and healthcare impact at the MedTech’s Got Talent Challenge Gala Finals. At MedTech’s black-tie night of nights,…
Cymerus™ MSCs Effective in Preclinical Model of Sepsis
5 December 2019 Melbourne, Australia: Australian stem cell and regenerative medicine company, Cynata Therapeutics Limited (ASX: CYP), announced today that it has received positive efficacy data from preclinical studies of its Cymerus™ mesenchymal stem cells (MSCs) in a…
CSL Continues to Advance R&D Capabilities
4 December 2019 Unique portfolio mix of plasma, cell and gene therapy, recombinant proteins and antibody assets highlighted at Research & Development Briefing. SYDNEY, Australia – CSL Limited (ASX:CSL; USOTC:CSLLY) is steadily advancing its Research & Development (R&D) pipeline…
ANDHealth Appoints Leading Global Healthcare Analyst & Strategist to Management Team
4 December 2019 ANDHealth today announced the appointment of leading healthcare communicator, analyst and strategist, Iain Scott, to the role of VP Stakeholder Engagement. A globally accomplished strategist, analyst and communicator, Iain has more than 20 years’ experience…
Digital Health Revolution
4 December 2019 Research Australia and the BioMelbourne Network are championing a Digital Health Revolution for Australia. Embracing digital technologies provides the opportunity to improve health outcomes, promote wellbeing and a sustainable health system, but it is going…
Positive DARRT-1 Data in Late-Stage Prostate Cancer
2 December 2019 Sydney: Noxopharm (ASX: NOX), an Australian drug development company, reports positive end-of-study data from its DARRT-1 Phase 1b trial. Commentary: Noxopharm Executive Chairman and CEO, Graham Kelly PhD “This is exciting data that validates our…
Opthea Raises A$50 million in Institutional Placement
2 December 2019 Melbourne, Australia – Opthea Limited (Opthea or the Company) (ASX: OPT), a clinical-stage biopharmaceutical company developing novel biologic therapies to treat back-of-the-eye diseases, today announced that the company has received commitments from sophisticated and institutional…
$3.5M ACRF grant to tackle cancer complexity
28 November 2019 Walter and Eliza Hall Institute researchers have won a $3.5 million ACRF grant to conquer the biggest challenges in cancer today – predicting and improving patients’ treatment response and overcoming drug resistance. The ACRF Program…
CSL Florey Medal recognises cell death research pioneers
27 November 2019 Walter and Eliza Hall Institute scientists Professor David Vaux AO and Professor Andreas Strasser have been jointly awarded the 2019 CSL Florey Medal for establishing a new field of research – the molecular biology of…
The Hon Greg Hunt MP Minister for Health: $100 million to increase clinical trial participation
29 November 2019 A joint media release with the Minister for Regional Services, Decentralisation and Local Government, the Hon Mark Coulton MP, announcing $100 million to improve the health of Australians in rural, remote and regional areas through…
$520M Growth Fund To Call Melbourne Home
28 November 2019 The Andrews Labor Government has welcomed news that the Australian Business Growth Fund will be based in Melbourne, cementing its spot as the home of capital funding. The $520 million Fund will help small to…
